SS Innovations International (NASDAQ: SSII) has announced the launch of Sri Lanka's first robotic cardiac surgery program at Kings Hospital Colombo, utilizing the company's SSi Mantra 3.0 surgical robotic system. The program's inaugural procedure was a robotic-assisted left internal mammary artery (LIMA) takedown, performed by Dr. Sudhir Srivastava, founder and chairman of SS Innovations, alongside Kings Hospital cardiothoracic surgeon Dr. Rajitha DeSilva. This development, highlighted in a recent company video, represents a significant step forward for cardiac care in Sri Lanka and underscores the growing adoption of robotic-assisted surgery in emerging markets.
The introduction of robotic cardiac surgery in Sri Lanka is a notable milestone for both the country's healthcare system and SS Innovations. According to the company, Kings Hospital has already completed more than 25 robotic procedures in just three weeks, demonstrating rapid adoption and proficiency with the new system. This early success suggests that the program could serve as a model for other hospitals in the region, potentially accelerating the spread of robotic surgery across South Asia. For patients, robotic-assisted cardiac surgery offers the promise of smaller incisions, reduced pain, and faster recovery times compared to traditional open-heart surgery.
SS Innovations reported 224 cumulative SSi Mantra installations across 12 countries at the end of the second quarter, reflecting its expanding global reach. The company's second-quarter revenue reached $13.9 million, while robotic procedures increased 143% year over year to 2,528, indicating rising utilization of its installed base. These figures suggest that the company is not only selling systems but also seeing increased use of its technology, which is crucial for long-term revenue growth and clinical validation. The launch in Sri Lanka adds to this momentum, as it opens a new market and demonstrates the system's versatility in complex cardiac procedures.
Looking ahead, SS Innovations is pursuing U.S. FDA clearance and European CE marking for the SSi Mantra system. These regulatory milestones are critical for the company's expansion into major markets and could significantly boost its credibility and adoption. If successful, these approvals would allow SS Innovations to compete more directly with established players in the global surgical robotics market. The company's progress in Sri Lanka, combined with its regulatory efforts, positions it as a rising contender in the field. For more information, visit the company's newsroom at https://ibn.fm/SSII. Additionally, the full terms of use and disclaimers are available at https://IBN.ai/Disclaimer.
This news matters because it highlights the tangible impact of SS Innovations' technology on a global scale. By enabling Sri Lanka's first robotic cardiac surgery program, the company is not only advancing its commercial interests but also contributing to the improvement of healthcare infrastructure in developing countries. The rapid adoption at Kings Hospital and the company's strong financial performance suggest that robotic surgery is gaining traction, which could lead to better patient outcomes and more efficient healthcare delivery. As SS Innovations continues to pursue regulatory approvals in the U.S. and Europe, its success in Sri Lanka serves as a proof point for the potential of its technology to transform surgical care worldwide.
